Analyst for Matt Sykes's questions to Adaptive Biotechnologies Corp (ADPT) leadership • Q4 2024
Question
An analyst on behalf of Matt Sykes from Goldman Sachs asked about the sustainability of the recent sequential growth cadence of approximately 1,200 clinical MRD units per quarter.
Answer
CFO Kyle Piskel affirmed that the company expects continued growth in both aggregate and percentage terms. He stated that the 2025 guidance midpoint assumes over 25% volume growth for the full year, driven by low penetration in core indications, which supports a long-term, durable growth outlook for the next 3 to 5 years.